ARUP Reminds Clinicians at PAINWeek: Use Quantitative Drug Testing Results to Delineate Partial vs. Full Dose Compliance
SALT LAKE CITY, Sept. 3, 2013 /PRNewswire/ -- ARUP Medical Director, Gwen McMillin, PhD, will present at The Cosmopolitan of Las Vegas on Thursday, September 5, as part of PAINWeek, The National Conference on Pain for Frontline Practitioners.
Although urine drug testing has become a routine component of many clinical environments, there is no well-accepted approach to interpreting the extent of medication adherence. McMillin' s presentation aims to review the interpretive value of quantitative urine drug testing results, and present the common misconception that quantitative drug screen results can extrapolate to a specific drug dose.
"PAINWeek is a great opportunity to discuss the limits of quantitative urine drug testing results, and what the results can and cannot infer," said McMillin.
Click here for more information regarding the presentation: What's in a Number? Can Quantitative Drug Testing Results Be Used to Delineate Partial vs. Full Dose Compliance?
The clinical utility of the proposed algorithm was recently challenged by investigators who reanalyzed the published supporting data, and concluded that random urine drug concentrations, even adjusted, could not reliably predict drug administration rates. This lack of prediction power is due in large part to a wide inter-individual variation in pharmacokinetics.
"The consequences of partial or non-compliance negatively impact patient care, the medical profession, and our society at large," said Gwen McMillin. "We hope this presentation will help guide clinicians with interpretation of quantitative urine drug testing results."
For more information regarding pain management services, visit ARUP's pain management page.
Founded in 1984, ARUP Laboratories is a leading national reference laboratory and a nonprofit enterprise of the University of Utah and its Department of Pathology. ARUP offers more than 3,000 tests and test combinations, ranging from routine screening tests to esoteric molecular and genetic assays. ARUP serves clients across the United States, including many of the nation's top university teaching hospitals and children's hospitals, as well as multihospital groups, major commercial laboratories, group purchasing organizations, military and other government facilities, and major clinics. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical and Experimental Pathology®.
801-583-2787, ext. 3635
SOURCE ARUP Laboratories